However, despite the excellent clinical outcomes observed with several chimeric antigen receptor T (CAR-T) cell products targeting CD19 or BCMA in the treatment of R/R B-cell malignancies and R/R multiple myeloma (MM), no CAR-T cell product has yet received regulatory approval for AML. This evidence concerns the gene CD19 and Miyoshi myopathy.